| Drug Name | risankizumab |
|---|---|
| Other Drug Names | ABBV-066; BI-655066; risankizumab |
| Chemical Name | immunoglobulin G1-kappa, anti-[Homo sapiens IL23A(interleukin 23 subunit alpha, IL-23A, IL23 subunit p19,IL23p19)], humanized monoclonal antibody; gamma1 heavy chain (1-449) [humanized VH (Homosapiens IGHV1-69*02 (79.40%) -(IGHD)-IGHJ5*01)[8.8.13] (1-120) -Homo sapiens IGHG1*01, G1m17,1 (CH1(121-218), hinge (219-233), CH2 L1.3>A (237), L1.2>A(238) (234-343), CH3 (344-448), CHS K2>del (449)) (121-449)], (223-214')-disulfide with kappa light chain (1’-214’)[humanized V-KAPPA (Homo sapiens IGKV1-27*01 (80.00%) -IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dimer (229-229":232-232")-bisdisulfide |
| CAS No. | 1612838-76-2 |
| UNII | 90ZX3Q3FR7 |
| Target-based Actions | IL-23 antagonist |
| Highest Status | Phase 3 Clinical |
| Originator Company | Boehringer Ingelheim Corp |
| Structure |
 |
Extended Information